Intestinal fibrosis is a serious complication of CD. It can lead to strictures and stenoses that narrow the lumen of the intestine and can cause dangerous obstructions. Approximately one in three people with CD develops strictures within 10 years of diagnosis and requires surgery to remove the diseased bowel. The most common site of surgical resection in patients with CD is the distal ileum.
3- Louis E.
- Collard A.
- Oger A.F.
- Degroote E.
- Aboul Nasr El Yafi F.A.
- Belaiche J.
Behaviour of Crohn's disease according to the Vienna classification: changing pattern over the course of the disease.
, 4- Burke J.P.
- Mulsow J.J.
- O'Keane C.
- Docherty N.G.
- Watson R.W.
- O'Connell P.R.
Fibrogenesis in Crohn's disease.
Furthermore, patients who have undergone surgery for fibrosis frequently relapse, developing intestinal inflammation and fibrotic strictures at the same location as the previous resection.
5- Van Assche G.
- Geboes K.
- Rutgeerts P.
Medical therapy for Crohn's disease strictures.
Anti–tumor necrosis factor-α therapy is effective at reducing inflammation in active CD, but the current thinking is that it is not effective at reducing fibrosis or fibrogenic gene expression.
6- Sorrentino D.
- Terrosu G.
- Avellini C.
Infliximab in Crohn's disease: a look at the (not so distant) future.
, 7Role of biologics and other therapies in stricturing Crohn's disease: what have we learnt so far?.
, 8- Burke J.P.
- Ferrante M.
- Dejaegher K.
- Watson R.W.
- Docherty N.G.
- De Hertogh G.
- Vermeire S.
- Rutgeerts P.
- D'Hoore A.
- Penninckx F.
- Geboes K.
- Van Assche G.
- O'Connell P.R.
Transcriptomic analysis of intestinal fibrosis-associated gene expression in response to medical therapy in Crohn's disease.
, 9First international summit on fibrosis in intestinal inflammation: mechanisms and biological therapies.
To our knowledge, there are no antifibrotic drugs available for use in patients with CD.
10- Szabò H.
- Fiorino G.
- Spinelli A.
- Rovida S.
- Repici A.
- Malesci A.C.
- Danese S.
Review article: anti-fibrotic agents for the treatment of Crohn's disease - lessons learnt from other diseases.
Fibrosis can be considered a pathological consequence of an excessive healing response. Normally, in response to tissue injury, the healing process includes the deposition of extracellular matrix proteins, the most abundant of which are members of the collagen family.
11Structure and biological activity of the extracellular matrix.
Thus, some degree of mild subclinical fibrosis may occur in all patients with CD.
12Intestinal fibrosis in IBD: a dynamic, multifactorial process.
, 13- Bhogal R.K.
- Stoica C.M.
- McGaha T.L.
- Bona C.A.
Molecular aspects of regulation of collagen gene expression in fibrosis.
The cell types that contribute to scar formation are mesenchymal cells, including myofibroblasts, smooth muscle cells, and fibroblasts.
4- Burke J.P.
- Mulsow J.J.
- O'Keane C.
- Docherty N.G.
- Watson R.W.
- O'Connell P.R.
Fibrogenesis in Crohn's disease.
Patients with CD and fibrosis experience accumulation of fibroblasts through the gut wall.
14- Regan M.C.
- Flavin B.M.
- Fitzpatrick J.M.
- O'Connell P.R.
Stricture formation in Crohn's disease: the role of intestinal fibroblasts.
Despite the urgent need to prevent or treat intestinal stricturing in patients with CD, little is known about the mechanisms underlying this process, in part because of a lack of suitable animal models for the study of intestinal fibrosis. There are many mouse models of intestinal inflammation,
15- Mizoguchi A.
- Mizoguchi E.
Animal models of IBD: linkage to human disease.
, 16- Nell S.
- Suerbaum S.
- Josenhans C.
The impact of the microbiota on the pathogenesis of IBD: lessons from mouse infection models.
but studies
17- Flier S.N.
- Tanjore H.
- Kokkotou E.G.
- Sugimoto H.
- Zeisberg M.
- Kalluri R.
Identification of epithelial to mesenchymal transition as a novel source of fibroblasts in intestinal fibrosis.
, 18- Rigby R.J.
- Hunt M.R.
- Scull B.P.
- Simmons J.G.
- Speck K.E.
- Helmrath M.A.
- Lund P.K.
A new animal model of postsurgical bowel inflammation and fibrosis: the effect of commensal microflora.
, 19- Grassl G.A.
- Valdez Y.
- Bergstrom K.S.
- Vallance B.A.
- Finlay B.B.
Chronic enteric salmonella infection in mice leads to severe and persistent intestinal fibrosis.
, 20- Vallance B.A.
- Gunawan M.I.
- Hewlett B.
- Bercik P.
- Van Kampen C.
- Galeazzi F.
- Sime P.J.
- Gauldie J.
- Collins S.M.
TGF-beta1 gene transfer to the mouse colon leads to intestinal fibrosis.
, 21- Motomura Y.
- Khan W.I.
- El-Sharkawy R.T.
- Verma-Gandhu M.
- Verdu E.F.
- Gauldie J.
- Collins S.M.
Induction of a fibrogenic response in mouse colon by overexpression of monocyte chemoattractant protein 1.
, 22- Lawrance I.C.
- Wu F.
- Leite A.Z.
- Willis J.
- West G.A.
- Fiocchi C.
- Chakravarti S.
A murine model of chronic inflammation-induced intestinal fibrosis down-regulated by antisense NF-kappa B.
of intestinal fibrosis have been limited to six colitis models. There are two genetic mouse models of spontaneous intestinal inflammation in the distal ileum: transgenic tumor necrosis factor
ΔARE and SAMP1/YitFc mice.
23- Kontoyiannis D.
- Boulougouris G.
- Manoloukos M.
- Armaka M.
- Apostolaki M.
- Pizarro T.
- Kotlyarov A.
- Forster I.
- Flavell R.
- Gaestel M.
- Tsichlis P.
- Cominelli F.
- Kollias G.
Genetic dissection of the cellular pathways and signaling mechanisms in modeled tumor necrosis factor-induced Crohn's-like inflammatory bowel disease.
, 24- Rivera-Nieves J.
- Bamias G.
- Vidrich A.
- Marini M.
- Pizarro T.T.
- McDuffie M.J.
- Moskaluk C.A.
- Cohn S.M.
- Cominelli F.
Emergence of perianal fistulizing disease in the SAMP1/YitFc mouse, a spontaneous model of chronic ileitis.
(SAMP1/YitFc mice are a subline of the senescence-accelerated mouse line.) Both of these models recapitulate some features of CD and have been used to study the development of chronic ileitis. The SAMP1/YitFc mouse is reported to develop fibrostenotic strictures at the age of 40 weeks
24- Rivera-Nieves J.
- Bamias G.
- Vidrich A.
- Marini M.
- Pizarro T.T.
- McDuffie M.J.
- Moskaluk C.A.
- Cohn S.M.
- Cominelli F.
Emergence of perianal fistulizing disease in the SAMP1/YitFc mouse, a spontaneous model of chronic ileitis.
but has not been used as a model for the treatment of intestinal fibrosis.
The Src homology 2 domain–containing inositol polyphosphate 5′-phosphatase (SHIP) is a hematopoietic-specific negative regulator of the phosphatidylinositol-3-kinase (PI3K) pathway. It removes the 5′ phosphate group from class IA PI3K-generated phosphatidylinositol 3,4,5-triphosphate, removing this important second messenger from the cell membrane, thereby discontinuing PI3K activity. SHIP
–/– mice were generated in 1998 by the laboratories of Krystal, Humphries, and colleagues.
25- Helgason C.D.
- Damen J.E.
- Rosten P.
- Grewal R.
- Sorensen P.
- Chappel S.M.
- Borowski A.
- Jirik F.
- Krystal G.
- Humphries R.K.
Targeted disruption of SHIP leads to hemopoietic perturbations, lung pathology, and a shortened life span.
SHIP
–/– mice have a myeloproliferative disorder, with a twofold to threefold increase in myeloid cells at different sites, lung pathological features, and a shortened life span.
25- Helgason C.D.
- Damen J.E.
- Rosten P.
- Grewal R.
- Sorensen P.
- Chappel S.M.
- Borowski A.
- Jirik F.
- Krystal G.
- Humphries R.K.
Targeted disruption of SHIP leads to hemopoietic perturbations, lung pathology, and a shortened life span.
Myeloid cells from these mice are hyperresponsive to various stimuli,
26- Sly L.M.
- Ho V.
- Antignano F.
- Ruschmann J.
- Hamilton M.
- Lam V.
- Rauh M.J.
- Krystal G.
The role of SHIP in macrophages.
and
in vivo differentiated SHIP
–/– macrophages are alternatively activated and constitutively express arginase I (ArgI).
27- Rauh M.J.
- Ho V.
- Pereira C.
- Sham A.
- Sly L.M.
- Lam V.
- Huxham L.
- Minchinton A.I.
- Mui A.
- Krystal G.
SHIP represses the generation of alternatively activated macrophages.
Recently, SHIP
–/– mice were reported to develop spontaneous intestinal CD-like inflammation.
28- Kerr W.G.
- Park M.Y.
- Maubert M.
- Engelman R.W.
SHIP deficiency causes Crohn's disease-like ileitis.
Herein, we confirm and extend these findings describing the inflammatory infiltrates, cytokine responses, and specific features that define ileal fibrosis. SHIP–/– mice develop thickened muscle layers, have increased collagen deposition, and accumulate fibroblasts in the affected ileum. In addition, the SHIP–/– mouse ilea have increased ArgI expression and arginase activity. More importantly, treating SHIP–/– mice with the arginase inhibitor, S-(2-boronoethyl)-l-cysteine (BEC), reduced ileal muscle hyperplasia and collagen deposition. These findings identify arginase activity as a novel therapeutic target for the treatment of intestinal fibrosis in CD.
Materials and Methods
Mice
SHIP heterozygotes, an F2 generation of C57BL/6 × 129Sv mice, were bred to generate SHIP+/+ and SHIP–/– littermates. Mice were maintained in sterilized filter-top cages and fed autoclaved food and water under specific pathogen-free conditions at the Animal Care Facility at the Child & Family Research Institute (Vancouver, BC). Sentinel mice were routinely screened for pathogens using a comprehensive serological profile service (Radil, Columbia, MO). All mice used were between the ages of 4 and 16 weeks. Experimentation was performed in accordance with institutional and Canadian Council on Animal Care guidelines.
Histological Characteristics
Mouse tissues were fixed in 10% neutral-buffered formalin at 4°C for 24 hours before paraffin processing. Paraffin sections (5-μm thick) were stained with H&E for histological examination. Masson's trichrome staining was performed according to the manufacturer's instructions (Sigma, St Louis, MO). Images were acquired and analyzed using a Zeiss Axiovert 200 microscope, a Zeiss AxiocamHR camera, and the Zeiss Axiovision 4.0 software imaging system.
Histological Analyses
Crypt depth and villus length were determined by counting epithelial cell nuclei from the base of crypts to the crypt-villus junction and from the crypt-villus junction to the villus tip, respectively, on uniform horizontal cross sections of crypts and villi. Goblet cells per crypt-villus were counted from the base of the crypt to the tip of the villus. Representative crypts-villi (10 per mouse) were counted in 5 to 10 H&E-stained sections of distal ileum for six 8-week-old SHIP+/+ and SHIP–/– mice by two individuals blinded to genotype (K.W.M. and A.E.C.). To count immune cell infiltrates, four representative fields of H&E-stained cross sections of seven untreated and seven BEC-treated SHIP–/– mouse ilea were obtained at ×20 magnification; infiltrates were counted according to nuclear morphological features in the circular muscularis externa and submucosa. The thickness of the muscularis externa from the serosa to the muscularis mucosa was measured at six points in 10 cross sections of distal ileum from seven untreated and seven BEC-treated SHIP–/– mice. In all cases, sections were nonconsecutive, separated by at least 50 μm, and counted at ×20 magnification.
IHC Procedures
For detection of CD3, F4/80, Gr-1/Ly6, ArgI, and nitrotyrosine slide-mounted 5-μm sections of FFPE tissues were deparaffinized and rehydrated. For CD3 and ArgI detection, heat-induced epitope retrieval was performed by immersing the slides in 1 mmol/L EDTA (pH 8.0) at 95°C for 20 minutes and allowing them to cool to room temperature. For F4/80, Gr-1, and nitrotyrosine detection, enzyme-induced epitope retrieval was performed by incubating samples with 20 μg/mL proteinase K in PBS for 15 minutes at room temperature. All slides were rinsed thoroughly in Tris-buffered saline with 0.1% Tween 20. Endogenous peroxidase activity was blocked with 1.5% H2O2 in PBS for 10 minutes. Endogenous avidin and biotin were blocked with an avidin-biotin blocking kit, according to the manufacturer's instructions (Vector Laboratories, Burlingame, CA). The primary antibodies used were rabbit anti-CD3 (Abcam, Cambridge, MA), rat anti–Gr-1 (Acris Antibodies, Herford, Germany), rat anti-F4/80 (AbD Serotec, Oxford, UK), mouse anti-ArgI (BD Biosciences, Mississauga, ON), and mouse anti-nitrotyrosine (Millipore, Billerica, MA). Blocking buffers, biotinylated secondary antibodies, and avidin–biotin–horseradish peroxidase or alkaline phosphatase complexes were prepared and used from rabbit IgG, rat IgG, or mouse-on-mouse immunohistochemistry (IHC) detection kits, according to the manufacturer's instructions (Vector Laboratories). Signals were detected with a diaminobenzidine chromogen system (Dako, Carpinteria, CA) or Vector Red (Vector Laboratories), and developed sections were counterstained with Harris' hematoxylin (Sigma). For vimentin staining, fresh tissue was flash frozen in dry ice-isopentane and embedded in optimal cutting temperature compound (Sakura Finetech; VWR Canada, Mississauga). Thaw-mounted sections were fixed in ice-cold acetone and blocked with the Mouse-on-Mouse detection system. Sections were incubated with mouse anti-vimentin antibody (BD Biosciences), followed by secondary Alexa 568–conjugated goat anti-mouse IgG antibody (Molecular Probes/Invitrogen, Eugene, OR). Sections were mounted in Vectashield mounting medium with DAPI (Vector Laboratories). Negative controls omitted primary antibodies and were performed for all antibodies.
Mouse Cytokine Arrays
Mouse-specific cytokine levels were determined in 150-mg samples of ilea from SHIP
+/+ mice and inflamed ilea from SHIP
–/– mice (
n = 4 per group) using the Mouse Cytokine Array Panel A kit from R&D Systems (Minneapolis, MN), according to the manufacturer's instructions. Protein (200 μg) was used for each array. Spot densities were quantified using ImageJ software version 1.43 (
http://rsbweb.nih.gov/ij/index.html) and exported to GraphPad Prism 5 version 5 (GraphPad Software Inc., San Diego, CA). Spot densities were corrected for individual background to diminish interarray variations.
Sircol Assays
Sections of fresh mouse distal ileum (30 to 100 mg) were minced with surgical scissors in 500 μL of 0.5 mol/L acetic acid with 10 mg/mL pepsin and agitated (at 1000 rpm with a VWR microplate shaker) overnight at room temperature. Tissue debris was removed and collagen was measured by the Sircol soluble collagen assay (Biocolor Ltd, Carrickfergus, UK), according to the manufacturer's instructions.
Arginase Assays
Fresh tissue samples were collected and homogenized in 1-mL arginase lysis buffer using a Polytron MR2100 bench-top homogenizer. Homogenates were cleared by centrifugation at 16,000 ×
g for 10 minutes at 4°C. Arginase activity was determined indirectly by measuring the concentration of urea generated by the arginase-dependent hydrolysis of
l-arginine, as previously described.
29Derivation and characterization of murine alternatively activated (M2) macrophages.
Mouse Treatment with BEC
BEC was synthesized by Dr Jean-Luc Boucher (Université Paris Descartes, Paris, France), as previously described.
30- Kim N.N.
- Cox J.D.
- Baggio R.F.
- Emig F.A.
- Mistry S.K.
- Harper S.L.
- Speicher D.W.
- Morris Jr, S.M.
- Ash D.E.
- Traish A.
- Christianson D.W.
Probing erectile function: s-(2-boronoethyl)-l-cysteine binds to arginase as a transition state analogue and enhances smooth muscle relaxation in human penile corpus cavernosum.
BEC was dissolved in deionized distilled water, adjusted to pH 7, and filter sterilized. BEC (100 μL of a 0.2% solution) was administered daily by oral gavage to 4-week-old SHIP
–/– mice for 2 weeks.
Statistical Analyses
Unpaired two-tailed Student's t-tests were performed when indicated using GraphPad Prism version 5 (GraphPad Software Inc.). For multiple comparisons made during cytokine assays, the Bonferroni correction was applied. Differences were considered significant at P < 0.05.
Discussion
The current treatment of CD includes therapies to reduce intestinal inflammation, improving quality of life for patients.
33Inflammatory bowel disease.
Despite improvements in therapies reducing inflammation, fibrosis remains a serious complication of disease.
34- Cosnes J.
- Nion-Larmurier I.
- Beaugerie L.
- Afchain P.
- Tiret E.
- Gendre J.P.
Impact of the increasing use of immunosuppressants in Crohn's disease on the need for intestinal surgery.
Research studying intestinal fibrosis has been challenging, in part, because of a lack of suitable animal models. Herein, we report that the SHIP
–/– mouse is a model of spontaneous intestinal inflammation that shares key features with CD. More importantly, these mice develop fibrosis, characterized by thickening of the muscle layers, collagen deposition, and fibroblast accumulation in the distal ileum (
Figure 5,
Figure 6).
There are several inducible murine models of intestinal fibrosis. Intestinal fibrosis can be induced in mouse colon and cecum by chronic
Salmonella enterica infection
19- Grassl G.A.
- Valdez Y.
- Bergstrom K.S.
- Vallance B.A.
- Finlay B.B.
Chronic enteric salmonella infection in mice leads to severe and persistent intestinal fibrosis.
and in the colon by overexpression of transforming growth factor-β1
20- Vallance B.A.
- Gunawan M.I.
- Hewlett B.
- Bercik P.
- Van Kampen C.
- Galeazzi F.
- Sime P.J.
- Gauldie J.
- Collins S.M.
TGF-beta1 gene transfer to the mouse colon leads to intestinal fibrosis.
or monocyte chemoattractant protein-1
21- Motomura Y.
- Khan W.I.
- El-Sharkawy R.T.
- Verma-Gandhu M.
- Verdu E.F.
- Gauldie J.
- Collins S.M.
Induction of a fibrogenic response in mouse colon by overexpression of monocyte chemoattractant protein 1.
or by repeated induction of colitis by trinitrobenzene sulfonic acid.
22- Lawrance I.C.
- Wu F.
- Leite A.Z.
- Willis J.
- West G.A.
- Fiocchi C.
- Chakravarti S.
A murine model of chronic inflammation-induced intestinal fibrosis down-regulated by antisense NF-kappa B.
These models do not cause fibrosis in the ileum, where it is most frequently found in patients with CD, and do not provide insight into spontaneous development of intestinal fibrosis. There are two genetic mouse models of spontaneous ileal inflammation. The tumor necrosis factor
ΔARE mouse develops ileal inflammation beginning before the age of 4 weeks, with inflammatory infiltrates in the submucosa containing scattered neutrophils and collections of histiocytes but do not display muscle thickening or collagen deposition.
23- Kontoyiannis D.
- Boulougouris G.
- Manoloukos M.
- Armaka M.
- Apostolaki M.
- Pizarro T.
- Kotlyarov A.
- Forster I.
- Flavell R.
- Gaestel M.
- Tsichlis P.
- Cominelli F.
- Kollias G.
Genetic dissection of the cellular pathways and signaling mechanisms in modeled tumor necrosis factor-induced Crohn's-like inflammatory bowel disease.
The SAMP1/YitFc mouse develops ileal inflammation with thickened circular muscle and collagen deposition in the submucosa and has perianal fistulae.
24- Rivera-Nieves J.
- Bamias G.
- Vidrich A.
- Marini M.
- Pizarro T.T.
- McDuffie M.J.
- Moskaluk C.A.
- Cohn S.M.
- Cominelli F.
Emergence of perianal fistulizing disease in the SAMP1/YitFc mouse, a spontaneous model of chronic ileitis.
Fibrosis develops slowly over 40 weeks in these mice, and the multigenic changes that cause this phenotype remain undefined.
Features reminiscent of CD in the SHIP
–/– mouse include both inflammatory and fibrotic components. CD is characterized by discontinuous inflammation primarily in the distal ileum,
35Classification of inflammatory bowel disease.
and SHIP
–/– mouse inflammation is discontinuous and restricted to the distal third of the ileum (
Figure 1B). Sites of inflammation in patients with CD are dominated by neutrophils,
36Inflammatory bowel disease: epidemiology, pathogenesis, and therapeutic opportunities.
and abundant neutrophils are present in the SHIP
–/– ileum (
Figure 3). An additional feature of CD is the formation of rudimentary granulomata in the ileum,
37- Xavier R.J.
- Podolsky D.K.
Unravelling the pathogenesis of inflammatory bowel disease.
and a diagnostic feature of the disease is the presence of multinucleated giant cells in the inflamed ileum.
38The granulomatous inflammatory response: a review.
, 39Inability of normal human intestinal macrophages to form multinucleated giant cells in response to cytokines.
Similarly, SHIP
–/– mice also have poorly formed granuloma containing multinucleated giant cells within the ileum (
Figure 2B). Fibrotic features of CD, such as muscle hyperplasia and collagen deposition,
40- Graham M.F.
- Diegelmann R.F.
- Elson C.O.
- Lindblad W.J.
- Gotschalk N.
- Gay S.
- Gay R.
Collagen content and types in the intestinal strictures of Crohn's disease.
are also present in our model (
Figure 5). Transmural fibroblast accumulation that occurs during intestinal fibrosis in patients with CD is also apparent in our model as an increase in vimentin
+ cells (
Figure 6A).
CD has traditionally been considered to be a Th1- and Th17-mediated disease based on increased production of interferon-γ, IL-12p70, and IL-23 in the early phases of inflammation.
2Crohn's disease: Th1, Th17 or both? the change of a paradigm: new immunological and genetic insights implicate Th17 cells in the pathogenesis of Crohn's disease.
, 41- Kugathasan S.
- Saubermann L.J.
- Smith L.
- Kou D.
- Itoh J.
- Binion D.G.
- Levine A.D.
- Blumberg R.S.
- Fiocchi C.
Mucosal T-cell immunoregulation varies in early and late inflammatory bowel disease.
, 42- Fuss I.J.
- Becker C.
- Yang Z.
- Groden C.
- Hornung R.L.
- Heller F.
- Neurath M.F.
- Strober W.
- Mannon P.J.
Both IL-12p70 and IL-23 are synthesized during active Crohn's disease and are down-regulated by treatment with anti-IL-12 p40 monoclonal antibody.
, 43- Monteleone G.
- Trapasso F.
- Parrello T.
- Biancone L.
- Stella A.
- Iuliano R.
- Luzza F.
- Fusco A.
- Pallone F.
Bioactive IL-18 expression is up-regulated in Crohn's disease.
Recently, the SHIP
–/– mouse was reported to be Th2 skewed,
44- Kuroda E.
- Antignano F.
- Ho V.W.
- Hughes M.R.
- Ruschmann J.
- Lam V.
- Kawakami T.
- Kerr W.G.
- McNagny K.M.
- Sly L.M.
- Krystal G.
SHIP represses Th2 skewing by inhibiting IL-4 production from basophils.
which was attributed to hyperactive basophils producing IL–4.
45- Kuroda E.
- Ho V.
- Ruschmann J.
- Antignano F.
- Hamilton M.
- Rauh M.J.
- Antov A.
- Flavell R.A.
- Sly L.M.
- Krystal G.
SHIP represses the generation of IL-3-induced M2 macrophages by inhibiting IL-4 production from basophils.
Unlike the inflammatory response characterized during active CD, fibrosis is a Th2-driven process.
46Fibrotic disease and the T(H)1/T(H)2 paradigm.
IL-4 and IL-13 stimulate type I collagen gene expression (
Col1a2)
47- Gillery P.
- Fertin C.
- Nicolas J.F.
- Chastang F.
- Kalis B.
- Banchereau J.
- Maquart F.X.
Interleukin-4 stimulates collagen gene expression in human fibroblast monolayer cultures: potential role in fibrosis.
and collagen production by fibroblasts.
47- Gillery P.
- Fertin C.
- Nicolas J.F.
- Chastang F.
- Kalis B.
- Banchereau J.
- Maquart F.X.
Interleukin-4 stimulates collagen gene expression in human fibroblast monolayer cultures: potential role in fibrosis.
, 48- Postlethwaite A.E.
- Holness M.A.
- Katai H.
- Raghow R.
Human fibroblasts synthesize elevated levels of extracellular matrix proteins in response to interleukin 4.
The inflamed and fibrotic SHIP
–/– mouse ilea express a mixed Th2 and Th17 cytokine profile, with significantly increased production of IL-4, IL-13, and IL-23 (
Figure 4). Alternatively activated macrophages, fibroblasts, and dysregulated Th2 and Th17 cytokine production have recently been suggested as the critical players in the development of an exaggerated healing response that leads to fibrosis.
49Fibrosis is regulated by Th2 and Th17 responses and by dynamic interactions between fibroblasts and macrophages.
The SHIP
–/– mouse has a myeloproliferative disorder and alternatively activated macrophages, abundant fibroblasts, and increased Th2 and Th17 cytokine responses that may cooperate to cause the dramatic ileal fibrosis in the SHIP
–/– mouse.
We recently found that PI3K, and specifically PI3Kp110δ, activity is required for robust expression of ArgI in response to IL-4.
50- Weisser S.B.
- McLarren K.W.
- Voglmaier N.
- van Netten-Thomas C.J.
- Antov A.
- Flavell R.A.
- LM Sly
Alternative activation of macrophages by IL-4 requires SHIP degradation.
Increased ArgI expression and arginase activity are features of murine alternatively activated macrophages
26- Sly L.M.
- Ho V.
- Antignano F.
- Ruschmann J.
- Hamilton M.
- Lam V.
- Rauh M.J.
- Krystal G.
The role of SHIP in macrophages.
;
in vivo SHIP
–/– mouse macrophages, including intestinal macrophages, are alternatively activated and constitutively express ArgI.
27- Rauh M.J.
- Ho V.
- Pereira C.
- Sham A.
- Sly L.M.
- Lam V.
- Huxham L.
- Minchinton A.I.
- Mui A.
- Krystal G.
SHIP represses the generation of alternatively activated macrophages.
, 51- Bishop J.L.
- Sly L.M.
- Krystal G.
- Finlay B.B.
The inositol phosphatase SHIP controls Salmonella enterica serovar Typhimurium infection in vivo.
On examination, ArgI expression and arginase activity were up-regulated in the distal ilea of SHIP
–/– mice (
Figure 6). Arginase could play an indirect role in the SHIP
–/– mouse ileal fibrosis by affecting inflammation. Alternatively, arginase could play a direct role in promoting fibrosis by increasing proline production, which is required for collagen biosynthesis, and/or by increasing ornithine production, which is metabolized by ornithine decarboxylase to produce polyamines that promote cell cycle progression and could lead to muscle hyperplasia.
52- Casero Jr, R.A.
- Marton L.J.
Targeting polyamine metabolism and function in cancer and other hyperproliferative diseases.
Based on this, we hypothesized that arginase inhibition could reduce intestinal fibrosis. Blocking arginase activity in the intestine with BEC has exacerbated inflammation, including immune cell infiltration, during
Citrobacter rodentium–induced colitis,
31- Gobert A.P.
- Cheng Y.
- Akhtar M.
- Mersey B.D.
- Blumberg D.R.
- Cross R.K.
- Chaturvedi R.
- Drachenberg C.B.
- Boucher J.L.
- Hacker A.
- Casero Jr, R.A.
- Wilson K.T.
Protective role of arginase in a mouse model of colitis.
but limits disease during
Helicobacter pylori infection by increasing NO-mediated killing of the pathogen.
32- Lewis N.D.
- Asim M.
- Barry D.P.
- Singh K.
- de Sablet T.
- Boucher J.L.
- Gobert A.P.
- Chaturvedi R.
- Wilson K.T.
Arginase II restricts host defense to Helicobacter pylori by attenuating inducible nitric oxide synthase translation in macrophages.
In our SHIP
–/– mouse genetic model of intestinal inflammation, BEC treatment reduced arginase activity and expression in the SHIP
–/– mouse ilea (
Figure 7A) but had no impact on the number of immune cell infiltrates or immune cell aggregates present in the SHIP
–/– mouse ilea (
Figure 7D). More importantly, BEC treatment reduced fibrosis, collagen deposition, and muscle hyperplasia in the SHIP
–/– mouse ilea (
Figure 7E).
SHIP acts by negatively regulating signaling through the PI3K pathway, which is reported to be an important signaling pathway in inflammatory bowel disease.
53Signaling pathways associated with inflammatory bowel disease.
Interestingly, human SHIP is encoded in the 2q37 region of human chromosome 2, where a polymorphism that is associated with early-onset inflammatory bowel disease has recently been described.
54- Imielinski M.
- Baldassano R.N.
- Griffiths A.
- Russell R.K.
- Annese V.
- Dubinsky M.
- et al.
Common variants at five new loci associated with early-onset inflammatory bowel disease.
Our study identifies SHIP deficiency as a genetic cause of murine intestinal inflammation with CD-like features, highlighting the importance of the SHIP and PI3K pathway as regulators of intestinal homeostasis. The power of this model of CD is that it accurately and consistently recapitulates both the ileal localization of inflammation and the ileal fibrosis that occurs in some patients with CD. ArgI activity correlates with fibrosis in two murine models of lung fibrosis,
55- Endo M.
- Oyadomari S.
- Terasaki Y.
- Takeya M.
- Suga M.
- Mori M.
- Gotoh T.
Induction of arginase I and II in bleomycin-induced fibrosis of mouse lung.
, 56- Mora A.L.
- Torres-Gonzalez E.
- Rojas M.
- Corredor C.
- Ritzenthaler J.
- Xu J.
- Roman J.
- Brigham K.
- Stecenko A.
Activation of alveolar macrophages via the alternative pathway in herpesvirus-induced lung fibrosis.
and arginase expression is significantly higher in resected gut tissues from patients with CD.
57- Horowitz S.
- Binion D.G.
- Nelson V.M.
- Kanaa Y.
- Javadi P.
- Lazarova Z.
- Andrekopoulos C.
- Kalyanaraman B.
- Otterson M.F.
- Rafiee P.
Increased arginase activity and endothelial dysfunction in human inflammatory bowel disease.
Arginase inhibition reduced the fibrosis that we observed in the SHIP
–/– mouse ileum, identifying arginase as a potential target for the treatment of intestinal fibrosis.
Article info
Publication history
Published online: May 09, 2011
Accepted:
March 21,
2011
Footnotes
Supported by a Canadian Association of Gastroenterology (CAG) summer studentship (A.E.C.), a Crohn's and Colitis Foundation of Canada grant in aid of research (L.M.S.), and a CAG/Canadian Institutes of Health Research/Crohn's and Colitis Foundation of Canada new investigator award (L.M.S.).
Supplemental material for this article can be found at http://ajp.amjpathol.org or at doi: 10.1016/j.ajpath.2011.03.018.
Copyright
© 2011 American Society for Investigative Pathology. Published by Elsevier Inc.